XOMA Royalty to Present at Investor Conferences in March

Rhea-AI Summary

XOMA Royalty (NASDAQ: XOMA), a biotech royalty aggregator, has announced its Executive Team's upcoming participation in investor conferences scheduled for March 2025. The company will engage in one-on-one investor meetings during these events.

Presentations will be accessible through the investor relations section of XOMA's website (www.xoma.com). Each presentation will remain archived and available for replay on the site for a 90-day period following the respective events.

News Market Reaction

-1.83%

1 alert

-1.83% News Effect

On the day this news was published, XOMA declined 1.83%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

EMERYVILLE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following investor conferences in March.  Management will also participate in one-on-one investor meetings.

T.D. Cowen 45th Annual Health Care Conference (March 3-5, 2025)
Format: Date: Time:	Corporate presentation Monday, March 3, 2025 11:10AM ET
Location: Link:	Boston, MA https://bit.ly/4jUN9w2
Leerink 2025 Global Healthcare Conference (March 9-12, 2025)
Format:	Fireside chat
Date:	Monday, March 10, 2025
Time:	2:20PM ET
Location: Link:	Miami Beach, FL https://bit.ly/4hxV1Cg

XOMA’s presentations can also be accessed by visiting the investor relations section of the Company’s website at www.xoma.com.  A replay of each presentation will be available and archived on the site for 90 days after the event.

About XOMA Royalty Corporation
XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health.  XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.  When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes.  The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate).  For more information about the Company and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn.

XOMA Investor Contact	XOMA Media Contact
Juliane Snowden	Kathy Vincent
XOMA Royalty	KV Consulting & Management
+1 646-438-9754	+1 310-403-8951
juliane.snowden@xoma.com	kathy@kathyvincent.com

FAQ

When will XOMA Royalty present at investor conferences in March 2025?

XOMA has announced its Executive Team will participate in investor conferences in March 2025, though specific dates were not provided in the announcement.

How long will XOMA's March 2025 investor presentations be available for replay?

XOMA's presentations will be archived and available for replay on their website for 90 days after each event.

Where can investors access XOMA's March 2025 conference presentations?

Investors can access XOMA's presentations through the investor relations section of the company's website at www.xoma.com.

Will XOMA's management team offer one-on-one meetings during the March 2025 conferences?

Yes, XOMA's management team will participate in one-on-one investor meetings during the March 2025 conferences.